| Literature DB >> 30140409 |
Majid Nejati1, Mohammad Ali Atlasi1, Mohammad Karimian1, Hossein Nikzad1, Abolfazl Azami Tameh1.
Abstract
OBJECTIVES: Stroke is the most common neurological disorder and genetic susceptibility has an important role in its etiology. Polymorphism in several genes such as lipoprotein lipase (LPL) is propounded as a risk for stroke. This meta-analysis investigated the association of rs285 and rs320 LPL polymorphism with stroke risk.Entities:
Keywords: Computational biology; Genetic polymorphism; Lipoprotein lipase; Meta-analysis; Stroke
Year: 2018 PMID: 30140409 PMCID: PMC6098956 DOI: 10.22038/IJBMS.2018.29009.7001
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Figure 1Flow diagram of the study selection process
Characteristics of included studies in the meta-analysis
| Country | Allele frequencies | Genotype frequencies | HWE | Type | Genotyping method | Author and year | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | Case | Control | |||||||||||
|
| T | G | T | G | TT | TG | GG | TT | TG | GG | ||||
| Chinese | 645 | 55 | 614 | 86 | 301 | 43 | 6 | 274 | 66 | 10 | 0.019 | Hemorrhagic | PCR-RFLP | Zhang |
| Chinese | 545 | 55 | 515 | 85 | 254 | 37 | 9 | 230 | 55 | 15 | <0.001 | Hemorrhagic | PCR-RFLP | Xing |
| Chinese | 218 | 22 | 242 | 52 | 99 | 20 | 1 | 99 | 44 | 4 | 0.735 | Hemorrhagic | PCR-RFLP | Gu |
| Chinese | 293 | 77 | 277 | 95 | 116 | 61 | 8 | 103 | 71 | 12 | 0.960 | Ischemic | PCR-RFLP | Xu |
| Japanese | 294 | 60 | 271 | 83 | 121 | 52 | 4 | 107 | 57 | 13 | 0.171 | Ischemic | PCR-RFLP | Shimo-Nakanishi |
|
| P+ | P- | P+ | P- | P+P+ | P+P- | P-P- | P+P+ | P-P+ | P-P- | ||||
| Chinese | 245 | 125 | 213 | 159 | 85 | 75 | 25 | 65 | 83 | 38 | 0.228 | Ischemic | PCR-RFLP | Xu |
| Japanese | 270 | 84 | 253 | 101 | 103 | 64 | 10 | 94 | 65 | 18 | 0.186 | Ischemic | PCR-RFLP | Shimo-Nakanishi |
Association results in the meta-analysis for rs320 polymorphism
| Variables |
| G | GG | TG | TG+GG | GG | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR |
| OR |
| OR |
| OR |
| OR |
| ||
| Total | 5 | 0.64 | < 0.001 | 0.47 | 0.001 | 0.65 | < 0.001 | 0.62 | < 0.001 | 0.51 | 0.005 |
| Subtype | |||||||||||
| Hemorrhagic | 3 | 0.58 | < 0.001 | 0.51 | 0.031 | 0.57 | < 0.001 | 0.56 | < 0.001 | 0.55 | 0.061 |
|
| 2 | 0.72 | 0.010 | 0.42 | 0.019 | 0.78 | 0.128 | 0.72 | 0.035 | 0.46 | 0.033 |
| HWE | |||||||||||
| Yes | 3 | 0.66 | < 0.001 | 0.40 | 0.008 | 0.69 | 0.009 | 0.65 | 0.001 | 0.44 | 0.017 |
| No | 2 | 0.61 | < 0.001 | 0.54 | 0.068 | 0.60 | 0.001 | 0.59 | < 0.001 | 0.59 | 0.112 |
| Country | |||||||||||
| China | 4 | 0.63 | < 0.001 | 0.53 | 0.016 | 0.62 | < 0.001 | 0.60 | < 0.001 | 0.58 | 0.039 |
| Sample size | |||||||||||
| <500 | 3 | 0.66 | < 0.001 | 0.40 | 0.008 | 0.693 | 0.009 | 0.65 | 0.001 | 0.44 | 0.017 |
| >500 | 2 | 0.61 | < 0.001 | 0.54 | 0.068 | 0.60 | 0.001 | 0.59 | < 0.001 | 0.59 | 0.112 |
OR: Odds Ratio; CI: Confidence Interval; HWE: Hardy-Weinberg equilibrium
Significant differences between the case and control groups are bolded
Summary risk difference and adjusted P-value for multiple testing using the BH-FDR method
| Variables |
| G | GG | TG | TG+GG | GG | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RD |
|
| RD |
|
| RD |
|
| RD |
|
| RD |
|
| ||
| Total | 5 | -0.05 | <0.001 | <0.001 | -0.03 | 0.001 | 0.001 | -0.07 | <0.001 | <0.001 | -0.09 | <0.001 | <0.001 | -0.02 | 0.004 | 0.005 |
| Subtype | ||||||||||||||||
| Hemorrhagic | 3 | -0.05 | <0.001 | <0.001 | -0.02 | 0.030 | 0.039 | -0.08 | <0.001 | <0.001 | -0.09 | <0.001 | <0.001 | -0.02 | 0.061 | 0.057 |
|
| 2 | -0.06 | 0.010 | 0.044 | -0.06 | 0.016 | 0.044 | -0.06 | 0.127 | 0.128 | -0.08 | 0.034 | 0.044 | -0.04 | 0.028 | 0.044 |
| HWE | ||||||||||||||||
| Yes | 3 | -0.06 | 0.004 | <0.001 | -0.05 | 0.006 | 0.011 | -0.08 | 0.009 | 0.011 | -0.10 | 0.001 | 0.003 | -0.03 | 0.014 | 0.017 |
| No | 2 | -0.05 | <0.001 | <0.001 | -0.02 | 0.066 | 0.085 | -0.07 | 0.001 | 0.002 | -0.07 | <0.001 | <0.001 | -0.0154 | 0.107 | 0.112 |
| Country | ||||||||||||||||
| China | 4 | -0.05 | <0.001 | <0.001 | -0.02 | 0.015 | 0.02 | -0.08 | <0.001 | <0.001 | -0.09 | <0.001 | <0.001 | -0.02 | 0.036 | 0.039 |
| Sample size | ||||||||||||||||
| <500 | 3 | -0.06 | 0.004 | <0.001 | -0.05 | 0.006 | 0.011 | -0.08 | 0.009 | 0.011 | -0.10 | 0.001 | 0.003 | -0.03 | 0.014 | 0.017 |
| >500 | 2 | -0.05 | <0.001 | <0.001 | -0.02 | 0.066 | 0.085 | -0.07 | 0.001 | 0.002 | -0.07 | <0.001 | <0.001 | -0.0154 | 0.107 | 0.112 |
RD: Risk difference; CI: Confidence Interval; HWE: Hardy-Weinberg equilibrium; FDR: P-value from Benjamini-Hochberg method control for false discovery rate
Figure 2Forest plot for the association of rs320 with stroke risk
Results of heterogeneity and publication bias in the meta-analysis for rs320 polymorphism
| Variables | G | GG | TG | TG+GG | GG | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Total | 0.636 | 0% | 0.094 | 0.806 | 0% | 0.197 | 0.554 | 0% | 0.251 | 0.643 | 0% | 0.227 | 0.805 | 0% | 0.250 |
| Subtype | |||||||||||||||
| Hemorrhagic | 0.684 | 0% | 0.030 | 0.802 | 0% | 0.158 | 0.717 | 0% | 0.216 | 0.662 | 0% | 0.105 | 0.847 | 0% | 0.167 |
| Ischemic | 0.587 | 0% | - | 0.303 | 6% | - | 0.862 | 0% | - | 0.890 | 0% | - | 0.278 | 15% | - |
| HWE | |||||||||||||||
| Yes | 0.315 | 13% | 0.114 | 0.527 | 0% | 0.551 | 0.283 | 21% | 0.176 | 0.321 | 12% | 0.037 | 0.514 | 0% | 0.598 |
| No | 0.987 | 0% | - | 0.994 | 0% | - | 0.932 | 0% | - | 0.962 | 0% | - | 0.989 | 0% | - |
| Country | |||||||||||||||
| China | 0.477 | 0% | 0.182 | 0.918 | 0% | 0.055 | 0.580 | 0% | 0.255 | 0.553 | 0% | 0.261 | 0.938 | 0% | 0.075 |
| Sample size | |||||||||||||||
| <500 | 0.315 | 13% | 0.114 | 0.527 | 0% | 0.551 | 0.283 | 21% | 0.176 | 0.321 | 12% | 0.037 | 0.514 | 0% | 0.598 |
| >500 | 0.987 | 0% | - | 0.994 | 0% | - | 0.932 | 0% | - | 0.962 | 0% | - | 0.989 | 0% | - |
Ph, Pheterogeneity (P<0.1 was considered as a significant difference). Pe, Pegger (P<0.05 was considered as a significant difference). HWE: Hardy-Weinberg equilibrium
Figure 3Funnel plot for the association of rs320 with stroke risk in total analysis
Figure 4Tertiary and secondary structures of LPL. Asn291Ser and Ser447Ter are located at center and C-terminal of LPL, respectively (A). The secondary structures of LPL for 291Asn and 291Ser phenotypes are coil and extended β-strands, respectively (B). The secondary structure for Ser447Ter polymorphism changes in the GOR method (B’)
Figure 5Hydrophobicity and average flexibility charts. After Asn291Ser substitution, the average flexibility (A) and hydrophobicity (B) of protein change in residues 314 to 322
Figure 6Results of RNAsnp. Enclosed area with marked differences in the mutant-type and wild-type LPL-hnRNA for rs320 (A) and rs285 (B). The possibility of wild-type and mutant sequences are illustrated in the top and bottom triangle of the graph, respectively. The polymorphic points are shown by yellow dots (A & B)